Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00574925 |
Recruitment Status :
Completed
First Posted : December 17, 2007
Last Update Posted : December 18, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The primary objective of this study is to investigate whether eradication treatment of Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the time to relapse in patients with gastroesophageal reflux disease (GERD).
A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within 14 days that are equal or above the critical value of 25.
The secondary objectives are
- To compare the time to relapse in the two H. pylori positive study groups with the H. pylori negative control group
- To compare the pattern of inflammation and atrophy in the two H. pylori positive treatment groups with the naturally H. pylori negative control group at relapse.
- All the above objectives analyzed for the efficacy subset that is the per-protocol patients broken down by effective H. pylori-eradication.
Secondary endpoints will be analyzed by the following parameters and their interactions:
- Treatment : Eradicated, Non-eradicated, Hp-negative control
- Esophagitis at study start: grades 0, A/B and C/D
- Gender
- Alcohol intake
-
NSAID/ASA intake (for histological results)
- Trial with medicinal product
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastroesophageal Reflux Disease (GERD) | Drug: Esomeprazole | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD) |
Study Start Date : | November 2003 |
Study Completion Date : | October 2007 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
For inclusion in the study the subject must fulfill all of the following criteria:
- Patients aged between 18 and 70 years.
- Chronic symptoms (>8 weeks) suggestive for GERD, as defined in Table 2 with or without reflux esophagitis grade A-D (Los Angeles classification)
- Indication for endoscopy due to GERD symptoms is given
- Written informed consent
Table 2: Lead GERD criteria
For inclusion in the study, all of the following lead GERD criteria should hold:
- At least one of the symptoms heartburn or regurgitation.
- At least 8 weeks ongoing symptoms.
- At least 3 times a week.
- At least moderate intensity, corresponding to light impairment in daily life and occasional need for drugs.
Exclusion criteria:
Any of the following is regarded as a criterion for exclusion from the study:
- Severe organic esophageal disease other than reflux esophagitis (e.g. carcinoma, esophageal stenosis).
- Gastric or duodenal ulcers
- Patients with visible Barrett's mucosa; no histological confirmation is required for exclusion
- History of previous esophageal or gastric surgery
- Alcohol or drug abuse
- Severe organic or psychiatric disease
- Pregnancy or lactation
- Women with child-bearing potential if no medically accepted contraceptive measures are used
- Contra-indication to amoxicillin, clarithromycin or esomeprazole (Nexium)
- Need for concomitant medication which could interfere with the investigational products (substrates of CYP3A4)
- Suspected or confirmed poor compliance
- Participation in a clinical study within 8 weeks prior to enrollment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00574925
Switzerland | |
University Hospital Zurich | |
Zurich, Switzerland |
Principal Investigator: | Werner Schwizer, MD | UniversitaetsSpital Zuerich |
ClinicalTrials.gov Identifier: | NCT00574925 |
Other Study ID Numbers: |
ACH-QBE-0201 |
First Posted: | December 17, 2007 Key Record Dates |
Last Update Posted: | December 18, 2007 |
Last Verified: | December 2007 |
H. pylori |
Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases |
Esomeprazole Anti-Ulcer Agents Gastrointestinal Agents Proton Pump Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |